JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB191468

Anti-CRISPR-Cas9 antibody [7A9-3A3]

4

(11 Reviews)

|

(79 Publications)

Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) is a mouse monoclonal antibody detecting CRISPR-Cas9 in Western Blot, ICC/IF.

- Over 50 publications

View Alternative Names

csn1, cas9, CRISPR-associated endonuclease Cas9, St-Cas9

4 Images
Immunocytochemistry/ Immunofluorescence - Anti-CRISPR-Cas9 antibody [7A9-3A3] (AB191468)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-CRISPR-Cas9 antibody [7A9-3A3] (AB191468)

ab191468 stained in NIH3T3 cells. Untreated and Cas9 transfected cells were fixed with 4% paraformaldehyde (10min) at room temperature and incubated with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% triton for 1h at room temperature to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab191468 at 10μg/ml and ab6046 (Rabbit polyclonal to beta tubulin) at 1ug/ml overnight at +4°C. The secondary antibodies were ab150117 (colored green) used at 1 ug/ml and ab150087 (pseudo-colored red) used at 2ug/ml for 1hour at room temperature. DAPI was used to stain the cell nuclei (colored blue) at a concentration of 1.43μM for 1hour at room temperature.

Western blot - Anti-CRISPR-Cas9 antibody [7A9-3A3] (AB191468)
  • WB

AbReview66778****

Western blot - Anti-CRISPR-Cas9 antibody [7A9-3A3] (AB191468)

Lane 1 : HeLa inducible Cas9 cell line in the absence of Doxcycline (-DOX)

Lane 2 : HeLa inducible Cas9 cell line in the treated for 24 hours in the presence of 1ug/ml of Doxcycline (+DOX).

Blot was probed with Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) 1 : 2000 and Anti-Tubulin Antibody DM1A (Sigma) as loading control. Shows specific band at 170kDA in Dox treated cells and tubulin band at 50kDa. Lysis and running Cells lysed in 1.5X Lammeli buffer +0.15M DTT syringed 10X with 25g needle and then boiled 100 degrees C for 10 minutes. 10ug of sample run out on 4-12% Bis Tris Nupage gel in 1X MOPS buffer WB protocol Western blot was performed by wet transfer of gel onto nitrocellulose membrane 100V for 2 h 4 degrees. Blocked in 5% milk PBST for 1 h room temp (1X PBS + 0.1% tween 20) incubated 24h at 4 degrees in 5% PBST with primary antibodies 1 : 2000 Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) as well as 1 : 3000 Anti Tubulin Mouse monoclonal DM1A antibody ( Sigma) Washed 3X PBST IgG anti mouse HRP 1 : 5000 (Jackson immunoscience) Washed 3x PBST Washed

HeLa cell line contains Cas9 under the control of a Doxcycline/Tetracycline inducible promotor (Tet on) Specific band at 170 kDa appears upon treatment with Doxcycline 1ug/ml for 24hours.1X PBS Developed using ECL prime kit (GE healthcare).

All lanes:

Western blot - Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468)

Predicted band size: 160 kDa

false

This image was courtesy of an anonymous AbReview

Western blot - Anti-CRISPR-Cas9 antibody [7A9-3A3] (AB191468)
  • WB

Lab

Western blot - Anti-CRISPR-Cas9 antibody [7A9-3A3] (AB191468)

Gel type : MOPS

Blocking buffer : 3% milk block

All lanes:

Western blot - Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) at 5 µg/mL

Lane 1:

NIH 3T3 whole cell lysate at 20 µg

Lane 2:

NIH 3T3 overexpressing Cas9 whole cell lysate at 20 µg

Secondary

All lanes:

Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/5000 dilution

Predicted band size: 160 kDa

Observed band size: 160 kDa

false

Exposure time: 4min

Western blot - Anti-CRISPR-Cas9 antibody [7A9-3A3] (AB191468)
  • WB

Lab

Western blot - Anti-CRISPR-Cas9 antibody [7A9-3A3] (AB191468)

We recommend using 3% milk as the blocking agent in Western Blot.

All lanes:

Western blot - Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) at 5 µg/mL

Lane 1:

S2 non-transfected cell lysate at 20 µg

Lane 2:

S2 cells transfected with CRISPR-Cas9 plasmid at 20 µg

Secondary

All lanes:

Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/5000 dilution

Predicted band size: 160 kDa

Observed band size: 160 kDa

true

Exposure time: 4min

  • HRP

    HRP Anti-CRISPR-Cas9 antibody [7A9-3A3]

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

7A9-3A3

Isotype

IgG1

Light chain type

kappa

Carrier free

No

Applications

ICC/IF, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

Ab191468 detects Cas9 and dCas9. This product has not been tested against SaCas9. Please contact Abcam Scientific Support for more information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Streptococcus pyogenes": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Transfected cell line - Streptococcus pyogenes": { "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "5-10 µg/mL", "ICCIF-species-notes": "<p></p>" }, "Transfected cell lysate - Streptococcus pyogenes": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1-5 µg/mL", "WB-species-notes": "<p>We recommend using 3% milk as the blocking agent for Western blot.</p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Product details

Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) is a House Mouse Monoclonal antibody and is validated for use in ICC/IF, WB in human, mouse, pig, rabbit, rat samples.

Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) has been cited over 55 times in peer reviewed journals and is trusted by the scientific community.

Abcams high quality validation processes ensure Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) has high sensitivity and specificity.

Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) has 11 independent reviews from customers.

Anti-CRISPR-Cas9 antibody [7A9-3A3] (ab191468) specifically detects CRISPR-Cas9 (UniProt ID: Q99ZW2; Molecular weight: 158kDa) and is sold in 100 ug selling sizes.

Antibody clone 7A9-3A3 is also available pre-conjugated to a variety of labels for your convenience - HRP (ab2258).

CRISPR-Cas9 technology enables precise gene editing to enhance cancer immunotherapy. It allows for the modification of immune cells to better target and destroy cancer cells, improving the efficacy of treatments like CAR-T cell therapy. Additionally, CRISPR-Cas9 can be used to identify and target immune checkpoint molecules, overcoming immune evasion by tumors.

Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

Properties and storage information

Form
Liquid
Purification technique
Affinity purification
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CRISPR-Cas9 also known simply as Cas9 is a protein that acts as a molecular scissor in gene editing. It has a molecular weight of approximately 160 kDa. Cas9 is a part of the CRISPR-Cas system originally discovered in bacteria where it serves as an adaptive immune system. In bacterial cells Cas9 targets and cleaves specific DNA sequences allowing for targeted gene modifications. While the expression of the CRISPR-Cas system occurs naturally in prokaryotes scientists now harness it in various organisms for genetic manipulation.
Biological function summary

The Cas9 protein functions as an integral part of the CRISPR-Cas9 complex which includes a guide RNA to direct the protein to specific DNA sequences. This complex enables precise cuts at targeted locations within the genome. The Cas9 protein size allows it to fit effectively within cells facilitating genome editing in areas such as research agriculture and therapeutics. The complexity of CRISPR-Cas9 also includes the interaction with other cellular components that assist in DNA repair post-cleavage.

Pathways

CRISPR-Cas9 plays a role in DNA repair pathways particularly non-homologous end joining and homologous recombination. After Cas9-induced DNA breaks these pathways become active to repair the cleaved DNA. The gene editing process facilitated by CRISPR-Cas9 often involves interaction with DNA repair proteins like ku70/80 and Rad51 in response to induced breaks. This allows for either the incorporation of new genetic material or the modification of existing genes.

CRISPR-Cas9 has potential in treating genetic disorders such as cystic fibrosis and Duchenne muscular dystrophy. By correcting mutated genes scientists aim to restore normal gene function offering potential therapeutic benefits. Additionally CRISPR-Cas9 relates indirectly to p53 a protein known for its tumor suppressor functions because gene-editing processes can sometimes activate p53-dependent pathways leading to cell cycle arrest or apoptosis. This highlights the importance of understanding the broader implications of CRISPR-Cas9 in therapeutic applications.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

CRISPR (clustered regularly interspaced short palindromic repeat) is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and Cas9. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA (Probable). Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer yielding blunt ends; Cas9 is inactive in the absence of the 2 guide RNAs (gRNA). Cas9 recognizes a 3'-G-rich protospacer adjacent motif (PAM, TGGTG in this organism) in the CRISPR repeat sequences to help distinguish self versus nonself, as targets within the bacterial CRISPR locus do not have PAMs. PAM recognition is also required for catalytic activity. When the CRISPR3/cas system consisting of cas9-cas1-cas2-csn2-CRISPR3 or just cas9-CRISPR3 is expressed in E.coli it prevents plasmids homologous to spacers 1 or 2 from transforming.
See full target information cas9

Publications (79)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 16:8716 PubMed41028718

2025

A histone-centric multi-omics study shows that increased H3K4 methylation sustains triple-negative breast cancer phenotypes.

Applications

Unspecified application

Species

Unspecified reactive species

Roberta Noberini,Giulia Robusti,Alessandro Vai,Evelyn Oliva Savoia,Maria Giovanna Jodice,Giovanni Bertalot,Betül Çat,Isabella Pallavicini,Giuseppina Bonizzi,Maria Capra,Claudia Anna Sangalli,Federico Zambelli,Nicola Fusco,Salvatore Pece,Giulio Pavesi,Saverio Minucci,Tiziana Bonaldi

Acta neuropathologica communications 13:164 PubMed40721826

2025

Melanoma antigens in pediatric medulloblastoma contribute to tumor heterogeneity and species-specificity of group 3 tumors.

Applications

Unspecified application

Species

Unspecified reactive species

Rebecca R J Collins,Rebecca R Florke Gee,Sima Tozandehjani,Tara Bayat,Maria Camila Hoyos Sanchez,Juan Sebastian Solano Gutierrez,Barbara Breznik,Anna K Lee,Samuel T Peters,Jon P Connelly,Shondra M Pruett-Miller,Martine F Roussel,Dinesh Rakheja,Heather S Tillman,Patrick Ryan Potts,Klementina Fon Tacer

Cancer cell international 25:272 PubMed40684193

2025

The DRP1 receptor FIS1 is critical to the expansion of triple-negative breast cancer tumor-initiating cells.

Applications

Unspecified application

Species

Unspecified reactive species

Tetiana Katrii,Tanya Freywald,Malkon G Estrada,Amr El Zawily,Behzad Toosi,Frederick S Vizeacoumar,Franco J Vizeacoumar,Andrew Freywald,Scot C Leary

RNA biology 22:1-15 PubMed40421600

2025

The oncogenic microRNA miR-222 promotes human LINE-1 retrotransposition.

Applications

Unspecified application

Species

Unspecified reactive species

Tomer Friehmann,Yamama Abu Mohsen,Yehuda Schlesinger,Lucy Ghantous,Lika Gamaev,Chavah Landau Zenilman,Avi Harazi,Eithan Galun,Daniel S Goldenberg

Cancer research 85:2890-2904 PubMed40327605

2025

Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Soyoung Lee,Kyunghwan Kim,Hye-Jin Jeong,Subin Choi,Himchan Cheng,Dayoung Kim,Soomin Heo,Jinhee Mun,Minjong Kim,Eunjin Lee,Yoon Ji Choi,Seon-Gyeong Lee,Eun A Lee,Yewon Jang,Kayeong Lim,Heon Seok Kim,Euihwan Jeong,Seung-Jae Myung,Deok-Beom Jung,Chang Sik Yu,In Ho Song,M Ryan Corces,Joo H Kang,Kyungjae Myung,Taejoon Kwon,Tae-Eun Park,Jinmyoung Joo,Seung Woo Cho

Cancer gene therapy 32:437-449 PubMed40089636

2025

Targeted inactivation of EWSR1 : : FLI1 gene in Ewing sarcoma via CRISPR/Cas9 driven by an Ewing-specific GGAA promoter.

Applications

Unspecified application

Species

Unspecified reactive species

Saint T Cervera,Selene Martínez,María Iranzo-Martínez,Laura Notario,Raquel M Melero-Fernández de Mera,Javier Alonso

BMC genomics 26:217 PubMed40045211

2025

Cas9-expressing cattle using the PiggyBac transposon all-in-one system.

Applications

Unspecified application

Species

Unspecified reactive species

Dong-Hyeok Kwon,Gyeong-Min Gim,Soo-Young Yum,Kyeong-Hyeon Eom,Song-Jeon Lee,Sang-Eun Han,Hee-Soo Kim,Hyeong-Jong Kim,Woo-Sung Lee,Woo-Jae Choi,Ji-Hyun Lee,Do-Yoon Kim,Dae-Jin Jung,Dae-Hyun Kim,Jun-Koo Yi,Byeong-Ho Moon,Won-You Lee,Goo Jang

PLoS pathogens 21:e1012531 PubMed39792924

2025

SLC35A2 gene product modulates paramyxovirus fusion events during infection.

Applications

Unspecified application

Species

Unspecified reactive species

Yanling Yang,Yuchen Wang,Danielle E Campbell,Heng-Wei Lee,Wandy Beatty,Leran Wang,Megan Baldridge,Carolina B López

Proceedings of the National Academy of Sciences of the United States of America 121:e2413298121 PubMed39585990

2024

Recurrent DNA nicks drive massive expansions of (GAA) repeats.

Applications

Unspecified application

Species

Unspecified reactive species

Liangzi Li,W Shem Scott,Alexandra N Khristich,Jillian F Armenia,Sergei M Mirkin

Nature protocols 20:1158-1195 PubMed39487259

2024

Design, performance, processing, and validation of a pooled CRISPR perturbation screen for bacterial toxins.

Applications

Unspecified application

Species

Unspecified reactive species

Songhai Tian,Yuhang Qin,Yuxuan Wu,Min Dong
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com